I am a medical epidemiologist (MD in 1988 at Paris V, specialisation in rheumatology in 1990, Paris V, and DrPH from Harvard School of Public Health in 1993) specialized in infectious diseases epidemiology. After working at WHO at the clinical research unit of the Global Program on AIDS (1993-1994), I spent five years in Ethiopia and two years in the Netherlands working as the Program Manager of the Ethio-Netherlands AIDS Research Project (1994-2001). In 2002, I joined Institut Pasteur to launch the Emerging Diseases Epidemiology unit. There, my focus has been on viral hepatitis C (North-Coordinator of the ANRS research site on viral hepatitis; www.hepnile.org) and emerging infections such as the SARS (Scientific Coordinator of the EPISARS project which aimed prevent the re-emergence of SARS through the control of its animal reservoir) and the MERS-CoV. I also have a strong teaching involvement, as co-Director and founder of the Pasteur-Cnam School of Public Health (http://ecole-pasteur.cnam.fr), and coordinator of a master in public health with strong focus on infectious diseases. In 2014, I was appointed as Director of the newly created Pasteur Centre for Global Health Research and Education.
Cliquez pour voir le graph
Connexions
Cliquez pour voir la ligne de temps
Ligne de temps
Présentation
Projets Transversaux
Projets
Publications
Télécharger-
2022Epidemiological evidence of nosocomial and zoonotic transmission of HTLV-1 in a large survey in rural population of central Africa., J Infect Dis 2022 Jul; (): .
-
2022Screening and vaccination against COVID-19 to minimise school closure: a modelling study., Lancet Infect Dis 2022 Apr; (): .
-
2022Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France., Lancet Reg Health Eur 2022 Feb; 13(): 100278.
-
2022Epidemiology and control of SARS-CoV-2 epidemics in partially vaccinated populations: a modeling study applied to France., BMC Med 2022 01; 20(1): 33.
-
2022Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22., Euro Surveill 2022 01; 27(1): .
-
2022Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines., Lancet Glob Health 2022 01; 10(1): e142-e147.
-
2021SARS-CoV-2 transmission across age groups in France and implications for control., Nat Commun 2021 11; 12(1): 6895.
-
2021Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection., J Infect Dis 2021 11; 224(9): 1489-1499.
-
2021Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2., J Infect Dis 2021 09; 224(6): 983-988.
-
2021Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France., Lancet Reg Health Eur 2021 Sep; 8(): 100171.
-
+Voir la liste complète de publications